Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Janney Capital Downgrades DepoMed Inc (DEPO) to Neutral
July 30, 2015 9:28 AM EDTJanney Capital downgraded DepoMed Inc (NASDAQ: DEPO) from Buy to Neutral.
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $31.87 yesterday.
... MoreRBC Capital Downgrades DepoMed Inc (DEPO) to Sector Perform
July 30, 2015 6:46 AM EDTRBC Capital downgraded DepoMed Inc (NASDAQ: DEPO) from Outperform to Sector Perform with a price target of $32.00 (from $26.00).
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $31.87 yesterday.
... MoreDepomed (DEPO) Tops Q2 EPS by 27c; Boosts FY15 Outlook
July 29, 2015 4:07 PM EDTDepomed (NASDAQ: DEPO) reported Q2 EPS of $0.27, $0.27 better than the analyst estimate of $0.00. Revenue for the quarter came in at $94.3 million versus the consensus estimate of $88.33 million.
Depomed sees FY2015 revenue of $320-340 million, versus prior guidance of $335-310 million. The company sees... More
Depomed (DEPO) Board Rejects Horizon Pharma's (HZNP) Revised Takeover Proposal
July 29, 2015 4:05 PM EDTDepomed (NASDAQ: DEPO) announced that its Board of Directors, after careful consideration and with the assistance of its independent financial and legal advisors, has unanimously rejected the purported revised, highly conditional, unsolicited and non-binding proposal from Horizon Pharma plc (NASDAQ: HZNP) ("Horizon") to acquire all of the outstanding shares of Depomed in an all-stock transaction (the "July 21 Proposal").
The Depomed Board concluded that the July 21 Proposal is inadequate and not in the best interests of Depomed and its shareholders. The Depomed Board believes that the... More
